Similarly, a notable observation was made regarding the combined effect of mTOR inhibitor and WEE1 inhibitor in both mutant neuroblastoma NRAS- and mutant KRAS-positive acute myelogenous leukemia (AML) cell lines and primary patient samples. Here, KRAS is linked to acute myeloid leukemia.